Finance

Lists
Outlook: 58.3% bullish·8.3% bearish
Go to analysis
THC:NYSE
Tenet Healthcare Corp
$261.99
+0.03%
(+0.090) 1D
$261.99
0.00% (0.00)
After hours
Closed: Sep 18, 4:00:03 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for THC...
Open
$263.49
High
$265.83
Low
$258.55
Mkt. cap
21.10B
Avg. vol.
716.49K
Volume
3.18M
P/E ratio
10.10
52-wk high
$283.05
52-wk low
$157.58
EPS
$25.93
Beta
1.23
Shares outstanding
80.52M
No. of employees
88K
Open
$263.49
High
$265.83
Low
$258.55
Mkt. cap
21.10B
Avg. vol.
716.49K
Volume
3.18M
P/E ratio
10.10
52-wk high
$283.05
52-wk low
$157.58
EPS
$25.93
Beta
1.23
Shares outstanding
80.52M
No. of employees
88K
News stories
From web sources and news partners
Profile
Tenet Healthcare Corporation is an American for-profit multinational healthcare services company based in Dallas. Through its brands, subsidiaries, joint ventures, and partnerships including United Surgical Partners International, the company operates around 65 hospitals and over 450 healthcare facilities. Tenet also runs Conifer Health Solutions, which provides healthcare support services to health systems and other clients. Since its founding in 1969, Tenet has expanded significantly. Among other major acquisitions and formations, Tenet founded Conifer Health Solutions in 2008, MedPost Urgent Care in 2014, and in 2013 acquired Vanguard Health Systems, Inc., an investor-owned hospital company whose operations complemented Tenet's existing business. The acquisition created the third-largest investor-owned hospital company in the United States in terms of revenue and the third-largest in number of hospitals owned. In 2015, Tenet acquired USPI, which created the largest operator of outpatient surgery centers in the U.S. In 2021, the company ranked 167th in the Fortune 500. Wikipedia
About Tenet Healthcare Corp
CEOSaum Sutaria
Employees88.5K
Founded1969
HeadquartersDallas, Texas, United States
SectorHealth care provider
Websitetenethealth.com
Analyst ratings
Based on 16 analysts giving stock ratings to THC in the past 3 months
Strong buy
Buy
15
Hold
1
Sell
0
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for THC in the last 3 months.
Highest
Current $261.99
$315.00 (+20.23%)
Average
$284.53 (+8.60%)
Lowest
$245.00 (-6.48%)
Analyst
Recommendation
Action
Price target
Projected
Date
Whit Mayo
Leerink Partners
Buy
Reiterated
-
-
09/17/2026
Craig Hettenbach
Morgan Stanley
Buy
Maintained
$274.00
+4.6%
09/14/2026
Benjamin Rossi
J.P. Morgan
Buy
Maintained
$315.00
+20.2%
09/01/2026
A.J. Rice
UBS
Buy
Maintained
$308.00
+17.6%
08/25/2026
Ann Hynes
Mizuho Securities
Buy
Maintained
$290.00
+10.7%
08/10/2026
Kevin Fischbeck
Bank of America Securities
Buy
Reiterated
$295.00
+12.6%
08/10/2026
Stephen Baxter
Wells Fargo
Buy
Reiterated
$281.00
+7.3%
07/31/2026
Scott Fidel
Goldman Sachs
Buy
Reiterated
$305.00
+16.4%
07/29/2026
Jason Cassorla
Guggenheim
Buy
Maintained
$283.00
+8%
07/27/2026
Michael Ha
Robert W. Baird
Hold
Maintained
$280.00
+6.9%
07/28/2026
Unknown Analyst
Stephens
Buy
Maintained
$285.00
+8.8%
07/27/2026
Raj Kumar CFA
Stephens
Buy
Maintained
$285.00
+8.8%
07/27/2026
David S Macdonald
Truist Financial
Buy
Reiterated
$290.00
+10.7%
07/28/2026
Ben Hendrix
RBC Capital
Buy
Reiterated
$283.00
+8%
07/26/2026
Ryan Langston
TD Cowen
Buy
Reiterated
$263.00
+0.4%
07/27/2026
Sarah James
Cantor Fitzgerald
Buy
Maintained
$245.00
-6.5%
07/23/2026
Andrew Mok CFA
Barclays
Buy
Maintained
$271.00
+3.4%
07/24/2026
Matthew Gillmor CFA
KeyBanc
Buy
Maintained
$225.00
-14.1%
05/01/2026
Last report
Jul 24, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$6.12 / $4.26
+43.54%beat
Revenue / Est. (USD)
5.63B / 5.44B
+3.53%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
5.29B
5.53B
5.37B
5.63B
Cost of goods sold
3.14B
3.23B
3.14B
3.22B
Cost of revenue
3.14B
3.23B
3.14B
3.22B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
102.00M
410.00M
102.00M
104.00M
Operating expense
1.34B
1.33B
1.27B
1.39B
Total operating expenses
4.47B
4.56B
4.40B
4.61B
Operating income
815.00M
965.00M
963.00M
1.02B
Other non operating income
31.00M
39.00M
43.00M
45.00M
EBT including unusual items
712.00M
681.00M
1.13B
1.34B
EBT excluding unusual items
704.00M
882.00M
852.00M
928.00M
Income tax expense
133.00M
37.00M
226.00M
295.00M
Effective tax rate
18.68%
5.43%
19.96%
22.01%
Other operating expenses
1.02B
687.00M
937.00M
1.07B
Net income
342.00M
371.00M
702.00M
826.00M
Net profit margin
6.47%
6.71%
13.08%
14.68%
Earnings per share
3.70
4.70
4.82
6.12
Interest and investment income
-
-
-
-
Interest expense
-206.00M
-205.00M
-205.00M
-204.00M
Net interest expenses
-206.00M
-205.00M
-205.00M
-204.00M
Depreciation and amortization charges
218.00M
231.00M
229.00M
215.00M
EBITDA
1.03B
1.20B
1.19B
1.24B
Gain or loss from assets sale
-20.00M
5.00M
-1.00M
-33.00M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps